How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,416 results for

Vasomotor Symptoms of Menopause

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause

Non-Pharmacologic Treatments for Vasomotor Symptoms Associated with Menopause Management Briefs eBrief-no117 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no117 -- Health Services Research & Development Management eBrief no. 117 » Issue 117 October 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence Report: Non-Pharmacologic Treatments (...) for Vasomotor Symptoms Associated with Menopause Vasomotor symptoms (VMS), which include hot flashes and night sweats, are the most common symptoms reported during the menopausal transition. VMS symptoms are experienced by as many as 80% of women with a mean age of onset of 51 years, and can last more than seven years. VMS can lead to increased healthcare encounters for symptom relief and reductions in quality of life. The degree to which VMS are bothersome is determined not only by how frequently

2016 Veterans Affairs - R&D

2. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society

Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Copyright @ 2015 The North American Menopause Society. Unauthorized reproduction of this article is prohibited. POSITION STATEMENT Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society Abstract Objective: To update and expand The North American Menopause Society’s evidence-based position (...) on nonhormonal management of menopause-associated vasomotor symptoms (VMS), previously a portion of the position statement on the management of VMS. Methods: NAMS enlisted clinical and research experts in the field and a reference librarian to identify and review available evidence. Five different electronic search engines were used to cull relevant literature. Using the literature, experts created a document for final approval by the NAMS Board of Trustees. Results: Nonhormonal management of VMS

2015 The North American Menopause Society

3. Exercise for vasomotor menopausal symptoms. (PubMed)

Exercise for vasomotor menopausal symptoms. Evidence suggests that many perimenopausal and early postmenopausal women will experience menopausal symptoms; hot flushes are the most common. Symptoms caused by fluctuating levels of oestrogen may be alleviated by hormone therapy (HT), but a marked global decline in its use has resulted from concerns about the risks and benefits of HT. Consequently, many women are seeking alternatives. As large numbers of women are choosing not to take HT (...) , it is increasingly important to identify evidence-based lifestyle modifications that have the potential to reduce vasomotor menopausal symptoms.To examine the effectiveness of any type of exercise intervention in the management of vasomotor symptoms in symptomatic perimenopausal and postmenopausal women.Searches of the following electronic bibliographic databases were performed to identify randomised controlled trials (RCTs): Cochrane Menstrual Disorders and Subfertility Group Specialised Trials Register

Full Text available with Trip Pro

2014 Cochrane

4. Managing Menopause Chapter 4 Vasomotor Symptoms

Managing Menopause Chapter 4 Vasomotor Symptoms Managing Menopause Chapter 4 Vasomotor Symptoms - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Supplement 2, Pages S31–S34 Managing Menopause Chapter 4 Vasomotor Symptoms DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. VMS affect 60% to 80% of women entering menopause. 1 Hot flashes are common (...) in the perimenopausal transition, when ovarian activity may be intermittent, and they have also been documented during the luteal and menstrual phases of the cycle in women with premenstrual dysphoric disorder. 2 After menopause, it is important to be alert to atypical features or to a lack of response to effective therapy, which might indicate an alternative cause of the symptoms. The differential diagnosis includes hyperthyroidism, anxiety, panic attack, hypertension, emotional flushing, neurologic flushing

2014 Society of Obstetricians and Gynaecologists of Canada

5. Vasomotor and physical menopausal symptoms are associated with sleep quality. (PubMed)

Vasomotor and physical menopausal symptoms are associated with sleep quality. Sleep disturbance is one of the common complaints in menopause. This study investigated the relationship between menopausal symptoms and sleep quality in middle-aged women.This cross-sectional observational study involved 634 women aged 44-56 years attending a healthcare center at Kangbuk Samsung Hospitals. Sleep quality was measured using the Pittsburgh Sleep Quality Index (PSQI).Multiple linear regression analysis (...) women. Multiple linear regression analysis adjusted for age, BMI, hypertension, diabetes, smoking, marital status, family income, education, employment status, parity, physical activity, depression symptoms, perceived stress and menopausal status showed that higher PSQI score was positively correlated with higher vasomotor(ß = 0.240, P = 0.020)and physical(ß = 0.572, P<0.001) scores.Vasomotor and physical menopause symptoms was related to poor sleep quality. Effective management strategies aimed

Full Text available with Trip Pro

2018 PLoS ONE

6. Attitudes to the prescription of menopause hormone therapy for vasomotor symptoms and osteoporosis for patients of different ages: A survey of gynecologists in Belgium. (PubMed)

Attitudes to the prescription of menopause hormone therapy for vasomotor symptoms and osteoporosis for patients of different ages: A survey of gynecologists in Belgium. The interpretation of the literature on menopause hormone therapy (MHT) has evolved enormously over the last decade. In recent years, guidelines have reinstated the place of MHT.This survey analyzes the prescription (initiation and maintenance) of MHT in relation to patient age and therapy indications.Two vignettes were sent (...) to gynecologists working in Belgium in a random survey. One vignette concerned the initiation of therapy for a woman who was either 52 or 62 years old, suffering either from severe vasomotor symptoms (VSM) or from osteoporosis. The second vignette concerned the maintenance of MHT or switching to another medication in a woman aged 62 years who suffered either from VSM (when stopping MHT) or from osteoporosis. The physicians were asked how they would treat these two patients.We analyzed 443 vignettes from 222

2019 Maturitas

7. Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy. (PubMed)

Retrospective analysis of phytoSERM for management of menopause-associated vasomotor symptoms and cognitive decline: a pilot study on pharmacogenomic effects of mitochondrial haplogroup and APOE genotype on therapeutic efficacy. PhytoSERM is a selective estrogen receptor beta (ERβ) modulator comprised of three phytoestrogens: genistein, daidzein, and S-equol. The PhytoSERM formulation promotes estrogenic action in the brain while largely inactive or inhibitory in reproductive tissue. A phase Ib (...) for menopause-associated hot flash and cognitive decline. While definitive determination of PhytoSERM efficacy is limited by the small sample size, these data provide a reasonable rationale to extend analyses to a larger study set powered to address statistical significance.

2019 Menopause

8. Treatment of Menopausal Vasomotor Symptoms with Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. (PubMed)

Treatment of Menopausal Vasomotor Symptoms with Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. The thermoregulatory center in the hypothalamus is stimulated by neurokinin 3 receptor (NK3R) activation and inhibited by estrogen negative-feedback. This balance is disrupted in menopause, producing vasomotor symptoms (VMS). Objective: To evaluate safety and efficacy of the NK3R antagonist fezolinetant in menopausal VMS. Design: 12-week, double-blind, randomized, placebo (...) of treatment. Improvements were achieved in all quality-of-life measures. Fezolinetant was well-tolerated. The most common fezolinetant-related adverse event was gastrointestinal disorder (n=6).Fezolinetant rapidly and significantly reduced moderate/severe VMS, supporting its potential as an effective nonhormonal treatment option for menopausal women.This study evaluated fezolinetant for the treatment of vasomotor symptoms in menopausal women. Treatment for 12 weeks reduced frequency and severity

2019 Journal of Clinical Endocrinology and Metabolism

9. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. (PubMed)

Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms. Objective: This study aimed to evaluate the effects of TX-001HR (17β-estradiol [E2] and progesterone [P4] in a single oral capsule) on cardiometabolic markers and outcomes. Methods: Four E2/P4 doses (1 mg/100 mg, 0.5 mg/100 mg, 0.5 mg/50 mg, 0.25 mg/50 mg) were compared with placebo in menopausal women with vasomotor symptoms (VMS) and a uterus in the phase 3 REPLENISH (ClinicalTrials.gov, NCT01942668

2019 Climacteric

10. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). (PubMed)

Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). This study determined whether two different formulations of hormone therapy (HT): oral conjugated equine estrogens (o-CEE; 0.45 mg/d, n = 209), transdermal 17β-estradiol (t-E2; 50 μg/d, n = 201) plus cyclic progesterone (Prometrium, 200 mg) or placebo (PBO, n (...)  = 243) affected sleep domains in participants of the Kronos Early Estrogen Prevention Study.Participants completed the Pittsburgh Sleep Quality Index at baseline and during the intervention at 6, 18, 36, and 48 months. Global sleep quality and individual sleep domain scores were compared between treatments using analysis of covariance, and correlated with vasomotor symptom (VMS) scores using Spearman correlation coefficients.Global Pittsburgh Sleep Quality Index scores (mean 6.3; 24% with score >8

Full Text available with Trip Pro

2017 Menopause

11. Vasomotor symptoms due to natural menopause; systematic review and network meta-analysis (NMA) of treatment effects from the NICE Menopause Guideline. (PubMed)

Vasomotor symptoms due to natural menopause; systematic review and network meta-analysis (NMA) of treatment effects from the NICE Menopause Guideline. Vasomotor symptoms (VMSs) are the hallmarks of menopause, occurring in approximately 75% of postmenopausal women in the UK, and are severe in 25%.To identify which treatments are most clinically effective for the relief of VMSs for women in natural menopause without hysterectomy.English publications in MEDLINE, Embase, and The Cochrane Library up (...) , but they also had significantly higher odds of discontinuation than placebo. Limited data were available for bleeding, therefore no conclusions could be made.For women who have not undergone hysterectomy, transdermal O+P was the most effective treatment for VMS relief.Which treatment best relieves menopause flushes? Results from the #NICE guideline network meta-analysis.© 2017 Royal College of Obstetricians and Gynaecologists.

Full Text available with Trip Pro

2017 BJOG : an international journal of obstetrics and gynaecology

12. Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial. (PubMed)

Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial. To compare the cost-utility of two exercise interventions relative to a control group for vasomotor menopausal symptoms.Economic evaluation taking a UK National Health Service and Personal Social Services perspective and a societal perspective.Primary care.Peri- and postmenopausal women who have not used hormone therapy in the past 3 months and experience ≥ 5 episodes of vasomotor (...) exercise social support groups are very likely to be cost-effective in the management of vasomotor menopausal symptoms.

Full Text available with Trip Pro

2017 PLoS ONE

13. Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms

Systematic review and meta-analysis: Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Isoflavones hold limited promise for the treatment of menopausal vasomotor symptoms Article Text Therapeutics Systematic review and meta-analysis Isoflavones hold limited promise

2014 Evidence-Based Medicine (Requires free registration)

14. Improving vasomotor symptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis. (PubMed)

Improving vasomotor symptoms; psychological symptoms; and health-related quality of life in peri- or post-menopausal women through yoga: An umbrella systematic review and meta-analysis. Vasomotor symptoms (VMS), commonly reported during menopausal transition, negatively affect psychological health and health-related quality of life (HRQoL). While hormone therapy is an effective treatment, its use is limited by concerns about possible harms. Thus, many women with VMS seek nonhormonal (...) , nonpharmacologic treatment options. However, evidence to guide clinical recommendations is inconclusive. This study reviewed the effectiveness of yoga, tai chi and qigong on vasomotor, psychological symptoms, and HRQoL in peri- or post-menopausal women.MEDLINE, Cochrane Database of Systematic Reviews, EMBASE, CINAHL and the Allied and Complementary Medicine Database were searched. Researchers identified systematic reviews (SR) or RCTs that evaluated yoga, tai chi, or qigong for vasomotor, psychological

2017 Complementary Therapies In Medicine

15. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. (PubMed)

Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone. To characterize the impact of TX-001HR on the relationship between vasomotor symptom (VMS) improvement and quality of life and sleep.REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, which evaluated four daily doses of 17β-estradiol and progesterone (E2/P4) combined in a single (...) , oral, softgel capsule in postmenopausal women (40-65 years) with a uterus and moderate to severe VMS (≥7/day or ≥50/week). In post hoc analyses, growth models were used to examine relationships between linear changes in VMS frequency and severity over 12 weeks and changes from baseline in the Menopause-Specific Quality of Life (MENQOL; total score and VMS domain) and the Medical Outcomes Study-Sleep (total score, sleep problems indices I and II) questionnaire outcomes at 12 weeks with treatment

Full Text available with Trip Pro

2018 Menopause

16. Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms? (PubMed)

Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms? No. Exercise doesn't decrease the frequency or severity of vasomotor menopausal symptoms in perimenopausal and postmenopausal women (strength of recommendation: A, systematic review of randomized controlled trials [RCTs] and consistent RCT).

2018 Journal of Family Practice

17. The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. (PubMed)

The role of sleep difficulties in the vasomotor menopausal symptoms and depressed mood relationships: an international pooled analysis of eight studies in the InterLACE consortium. Many women experience both vasomotor menopausal symptoms (VMS) and depressed mood at midlife, but little is known regarding the prospective bi-directional relationships between VMS and depressed mood and the role of sleep difficulties in both directions.A pooled analysis was conducted using data from 21 312 women

Full Text available with Trip Pro

2018 Psychological Medicine

18. N-3 Polyunsatured Fatty Acids in Menopausal Transition: A Systematic Review of Depressive and Cognitive Disorders with Accompanying Vasomotor Symptoms (PubMed)

N-3 Polyunsatured Fatty Acids in Menopausal Transition: A Systematic Review of Depressive and Cognitive Disorders with Accompanying Vasomotor Symptoms Depression is one of the most important health problems worldwide. Women are 2.5 times more likely to experience major depression than men. Evidence suggests that some women might experience an increased risk for developing depression during “windows of vulnerability”, i.e., when exposed to intense hormone fluctuations (...) , such as the menopause transition. Indeed, this period is associated with different symptoms, including vasomotor, depressive, and cognitive symptoms, which have all been shown to worsen as women approach menopause. Even though hormonal therapy represents the most effective treatment, side effects have been reported by several studies. Therefore, an increased number of women might prefer the use of alternative medicine for treating menopausal symptoms. N-3 long-chain polyunsaturated fatty acids (n-3 LCPUFAs

Full Text available with Trip Pro

2018 International journal of molecular sciences

19. A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. A Study of NT-814 in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms (SWITCH-1) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03596762 Recruitment Status : Recruiting

2018 Clinical Trials

20. Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS). (PubMed)

Vasomotor symptoms in women over 60: results from the Data Registry on Experiences of Aging, Menopause, and Sexuality (DREAMS). Frequency of vasomotor symptoms (VMS) in older women and the contributing factors are largely undefined. We measured the frequency of moderate-to-severe vasomotor symptoms (msVMS) in women ≥60 years of age and examined their characteristics to determine factors that may associate with VMS in older women.A cross-sectional survey was completed using the Menopause Health (...) Questionnaire from the Data Registry on Experiences of Aging, Menopause, and Sexuality. Data were collected from women presenting for menopause consultation to Mayo Clinic, Rochester, MN, from January 1, 2006 to October 7, 2014. We created a binary variable where women were classified as having msVMS bother if they reported "quite a bit" or "extremely" compared with women reporting "not at all" or "a little bit." Women with and without msVMS were evaluated by menopause type, self-rated heath, current

2018 Menopause

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>